Advair vs. Xopenex
See how Advair and Xopenex compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Advair is a twice-daily combination inhaler that controls asthma and COPD over time, while Xopenex is a short-acting bronchodilator used to relieve sudden breathing symptoms.
Advair combines an inhaled steroid with a long-acting bronchodilator and is not meant for fast relief, while Xopenex works quickly but does not treat airway inflammation.
Many patients use these drugs together, with Advair for daily control and Xopenex as a rescue inhaler when symptoms flare.
Advair vs. Xopenex Drug Summary
Advair
Advair is a combination corticosteroid and long-acting beta2-agonist (ICS/LABA) inhaler used for daily maintenance treatment of asthma in people 4 and older and for COPD. It is taken twice a day through a Diskus powder inhaler and is not intended for fast relief of a breathing attack.
Xopenex
Xopenex is a short-acting beta2-agonist bronchodilator used to treat or prevent sudden bronchospasm in asthma and other reversible airway diseases. It is delivered through a nebulizer solution or an HFA inhaler and works within minutes.
Advair vs. Xopenex Side Effects
Advair
Xopenex
Advair vs. Xopenex Dosage
Advair
Xopenex
| STAGE | DOSE | WHEN |
| Starting dose | 100 mcg/50 mcg twice daily | At the start |
| Maximum dose | 500 mcg/50 mcg twice daily | If needed |
| Dose changes | 2 increases | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 0.31 mg three times daily | At the start |
| Maximum dose | 90 mcg (2 inhalations) q4-6h | If needed |
| Dose changes | 4 increases | As tolerated |
Advair
| STAGE | DOSE | WHEN |
| Starting dose | 100 mcg/50 mcg twice daily | At the start |
| Maximum dose | 500 mcg/50 mcg twice daily | If needed |
| Dose changes | 2 increases | As tolerated |
Xopenex
| STAGE | DOSE | WHEN |
| Starting dose | 0.31 mg three times daily | At the start |
| Maximum dose | 90 mcg (2 inhalations) q4-6h | If needed |
| Dose changes | 4 increases | As tolerated |
Advair vs. Xopenex Indications
Advair
Advair is approved for the ongoing maintenance treatment of asthma in patients 4 years and older and for maintenance treatment of airflow obstruction caused by COPD, including chronic bronchitis and emphysema. It is also used to reduce the number of COPD exacerbations in people who have had them before. It is not meant to stop a breathing attack that is already happening.
Long-term asthma control in patients 4 and older
Maintenance treatment of COPD airflow obstruction
Reduces frequency of COPD exacerbations
Taken twice daily on a fixed schedule
Xopenex
Xopenex is approved for the treatment or prevention of bronchospasm in people with asthma or other reversible obstructive airway diseases. It is used as a rescue medication when breathing symptoms occur or before activities known to trigger them, such as exercise. It is not approved as a daily controller therapy for asthma or COPD.
Fast relief of acute asthma symptoms
Prevention of exercise-induced bronchospasm
Used with nebulizer or HFA inhaler
Often paired with a daily controller inhaler
Advair vs. Xopenex Pros and Cons
Advair
Advair addresses both the inflammation and the airway tightening involved in asthma and COPD, making it a mainstay of daily disease control. Because it is a combination product taken on a schedule, it works best alongside a separate rescue inhaler for sudden symptoms.
Pros
Treats both inflammation and bronchoconstriction in one inhaler
FDA-approved for both asthma and COPD maintenance
Available as a lower-cost generic (Wixela Inhub)
Reduces long-term risk of COPD exacerbations
Cons
Not effective for sudden breathing attacks
Requires correct twice-daily inhaler technique
Long-acting beta-agonist component carries an asthma safety history
Roughly $300 to $500 per month without insurance, higher than Xopenex
Xopenex
Xopenex offers quick relief when airways suddenly tighten, which makes it a common rescue partner to a controller like Advair. It does not treat the underlying inflammation that drives asthma or COPD, so it is not meant to replace daily maintenance therapy.
Pros
Works within minutes for acute symptom relief
Available as both nebulizer solution and HFA inhaler
Single-isomer formula intended to limit side effects seen with racemic albuterol
Roughly $55 to $120 per month without insurance, lower than Advair
Cons
Does not treat airway inflammation
May require dosing as often as every 4 hours
Overuse can raise heart rate and blood pressure
Not approved to reduce COPD exacerbations
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.